Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMYNYSEHealthcare
$59.75
down -0.82 (-1.35%)

1-Year Price

+25.98% past year
Bristol-Myers Squibb Company (BMY) 1-year price chart: up 25.98% from $47.43 on Oct 2025 to $59.75 on Oct 2026. Closing range $42.60 to $68.09.

EquityGlimpse Score

Overall
7.0/10
Narrow Moat

Some competitive advantages, though less durable than a wide moat.

Growth
6

Valuation, profitability, financial health, dividend and sentiment scores for Bristol-Myers Squibb Company (BMY) are available to EquityGlimpse members.

Market Cap
122.05B
P/E Ratio
15.59
EPS
$3.46
52W High
$68.64
52W Low
$42.52
Volume
12.82M
Beta
0.23
Dividend Yield
4.58%
Fair value estimate: sign up to see
Is BMY over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
2.28
Price to Book
5.96
EV/EBITDA
9.65
Free CF per Share
$6.29
Op. CF per Share
$6.94
Debt to Equity
2.55
Gross Margin
71.08%
Net Margin
14.64%

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

CEO
Christopher Boerner
Industry
Drug Manufacturers - General
Employees
32,500
IPO Date
1972-06-01
Country
US
Website
Unlock Full Analysis

Get the complete picture on Bristol-Myers Squibb Company

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for BMY and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.